Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of TAK-875 (fasiglifam),
once daily (QD), in participants with type 2 diabetes mellitus (T2DM).